[go: up one dir, main page]

PE20181288A1 - Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer - Google Patents

Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer

Info

Publication number
PE20181288A1
PE20181288A1 PE2018000611A PE2018000611A PE20181288A1 PE 20181288 A1 PE20181288 A1 PE 20181288A1 PE 2018000611 A PE2018000611 A PE 2018000611A PE 2018000611 A PE2018000611 A PE 2018000611A PE 20181288 A1 PE20181288 A1 PE 20181288A1
Authority
PE
Peru
Prior art keywords
cancer
treatment
alkyl
derivatives used
dihydroimidazopyrazinone
Prior art date
Application number
PE2018000611A
Other languages
English (en)
Inventor
Richard Andrew Ward
Clifford David Jones
Steven Swallow
Mark Andrew Graham
Andrew Hornby Dobson
James Francis Mccabe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20181288A1 publication Critical patent/PE20181288A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a un compuesto derivado de dihidroimidazopirazinona de formula (I), donde R1 es H, alquilo C1-3, entre otros; R2 es fenilo, piridinilo o pirimidinilo, donde piridinilo o pirimidinilo estan opcionalmente sustituidos en 1 atomo de carbono en el anillo por un sustituyente que consiste en alquilo C1-C3, difluorometilo, trifluorometilo; R3 es H, alquilo C1-C3, entre otros. Dichos compuestos utiles en el tratamiento del cancer tales como cancer de pancreas, colorrectal, entre otros
PE2018000611A 2015-11-09 2016-11-08 Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer PE20181288A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252726P 2015-11-09 2015-11-09
US201662401351P 2016-09-29 2016-09-29

Publications (1)

Publication Number Publication Date
PE20181288A1 true PE20181288A1 (es) 2018-08-07

Family

ID=57241113

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000611A PE20181288A1 (es) 2015-11-09 2016-11-08 Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer

Country Status (35)

Country Link
US (2) US9902731B2 (es)
EP (1) EP3374359B1 (es)
JP (1) JP6877423B2 (es)
KR (1) KR20180074788A (es)
CN (1) CN108349983B (es)
AU (1) AU2016351813B2 (es)
BR (1) BR112018008397B1 (es)
CA (1) CA3003549A1 (es)
CL (1) CL2018001226A1 (es)
CO (1) CO2018004857A2 (es)
CR (1) CR20180316A (es)
CY (1) CY1123627T1 (es)
DK (1) DK3374359T3 (es)
EA (1) EA038028B1 (es)
ES (1) ES2780650T3 (es)
HR (1) HRP20200342T1 (es)
IL (1) IL258953A (es)
LT (1) LT3374359T (es)
ME (1) ME03770B (es)
MX (1) MX376639B (es)
MY (1) MY197626A (es)
NI (1) NI201800058A (es)
PE (1) PE20181288A1 (es)
PH (1) PH12018500987A1 (es)
PL (1) PL3374359T3 (es)
PT (1) PT3374359T (es)
RS (1) RS60155B1 (es)
SG (1) SG11201803066VA (es)
SI (1) SI3374359T1 (es)
SM (1) SMT202000152T1 (es)
SV (1) SV2018005687A (es)
TN (1) TN2018000119A1 (es)
TW (1) TWI730012B (es)
WO (1) WO2017080979A1 (es)
ZA (1) ZA201803742B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291017B2 (en) 2015-10-21 2023-11-01 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
CR20180316A (es) * 2015-11-09 2018-10-05 Astrazeneca Ab Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
CN110577543B (zh) * 2018-10-10 2022-07-08 深圳市塔吉瑞生物医药有限公司 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途
CN113518779B (zh) 2019-03-28 2024-03-15 江苏恒瑞医药股份有限公司 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
US20220204512A1 (en) 2019-05-24 2022-06-30 Jiangsu Hengrui Medicine Co., Ltd. Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines
CA3140475A1 (en) * 2019-06-06 2020-12-10 Wei-Guo Su Tricyclic compounds and their use
WO2021110893A1 (en) * 2019-12-05 2021-06-10 Astrazeneca Ab Process and intermediates for the production of formula (i)
JP7409719B2 (ja) * 2019-12-06 2024-01-09 徳昇済医薬（無錫）有限公司 Ｅｒｋ阻害剤としてのチアゾロラクタム系化合物およびその使用
JP2023543080A (ja) 2020-09-29 2023-10-12 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 ピロロ複素環系誘導体の結晶及びその製造方法
CN117529321A (zh) * 2021-06-18 2024-02-06 上海德琪医药科技有限公司 Erk抑制剂和kras抑制剂的组合及其用途
WO2022268065A1 (en) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Compounds as erk inhibitors
AU2022320304A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4426704A1 (en) 2021-11-04 2024-09-11 Skyhawk Therapeutics, Inc. Condensed pyridazine amine derivatives treating sca3
EP4514807B1 (en) 2022-04-27 2025-12-17 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
US20250304593A1 (en) 2022-05-12 2025-10-02 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2004041826A1 (en) * 2002-11-06 2004-05-21 Merck Sharp & Dohme Limited Imidazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic
GB0520958D0 (en) 2005-10-14 2005-11-23 Cyclacel Ltd Compound
CN101611007A (zh) * 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
MY170715A (en) * 2010-12-22 2019-08-27 Janssen Pharmaceutica Nv 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace)
CN104703987B (zh) * 2011-10-10 2017-05-03 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
JP2013166727A (ja) * 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
SMT201800282T1 (it) 2012-03-01 2018-07-17 Genentech Inc Inibitori delle serina/treonina chinasi
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
UA120506C2 (uk) * 2013-12-06 2019-12-26 Дженентек, Інк. Інгібітори серин/треонінкіназ
CN105848723B (zh) 2013-12-30 2019-08-02 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
EP3089980B1 (en) * 2013-12-30 2018-01-31 Array Biopharma, Inc. Serine/threonine kinase inhibitors
EP3494971B1 (en) 2014-04-09 2024-07-24 Genentech, Inc. Salts of erk inhibitors
US10412619B2 (en) * 2014-11-14 2019-09-10 Qualcomm Incorporated Buffer status report for eDCS
WO2016162325A1 (en) * 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
CA2987963C (en) 2015-06-03 2023-01-24 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
CN107849046B (zh) 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
CR20180316A (es) * 2015-11-09 2018-10-05 Astrazeneca Ab Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer

Also Published As

Publication number Publication date
KR20180074788A (ko) 2018-07-03
DK3374359T3 (da) 2020-03-30
HK1256283A1 (en) 2019-09-20
TN2018000119A1 (en) 2019-10-04
EA038028B1 (ru) 2021-06-24
EP3374359A1 (en) 2018-09-19
AU2016351813A1 (en) 2018-06-21
CN108349983B (zh) 2021-02-26
TWI730012B (zh) 2021-06-11
WO2017080979A1 (en) 2017-05-18
BR112018008397A2 (pt) 2018-10-23
CL2018001226A1 (es) 2018-10-05
SI3374359T1 (sl) 2020-04-30
US10202391B2 (en) 2019-02-12
MX376639B (es) 2025-03-07
JP2019503337A (ja) 2019-02-07
EA201891063A1 (ru) 2018-12-28
US20170204100A1 (en) 2017-07-20
RS60155B1 (sr) 2020-05-29
CY1123627T1 (el) 2022-03-24
BR112018008397B1 (pt) 2023-12-12
NI201800058A (es) 2018-10-18
TW201728586A (zh) 2017-08-16
PL3374359T3 (pl) 2020-06-29
IL258953A (en) 2018-06-28
ME03770B (me) 2021-04-20
SMT202000152T1 (it) 2020-05-08
CN108349983A (zh) 2018-07-31
ZA201803742B (en) 2020-08-26
US20180237443A1 (en) 2018-08-23
PH12018500987A1 (en) 2019-01-28
CR20180316A (es) 2018-10-05
MX2018005725A (es) 2018-08-14
HRP20200342T1 (hr) 2020-06-12
CO2018004857A2 (es) 2018-07-19
CA3003549A1 (en) 2017-05-18
JP6877423B2 (ja) 2021-05-26
ES2780650T3 (es) 2020-08-26
LT3374359T (lt) 2020-03-25
AU2016351813B2 (en) 2019-05-30
EP3374359B1 (en) 2020-01-08
US9902731B2 (en) 2018-02-27
MY197626A (en) 2023-06-29
SG11201803066VA (en) 2018-05-30
SV2018005687A (es) 2018-07-20
PT3374359T (pt) 2020-03-27

Similar Documents

Publication Publication Date Title
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CU24572B1 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas
PH12017501016A1 (en) Triazolopyrimidine compounds and uses thereof
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
PE20181145A1 (es) Compuestos de piridina
PH12016502154A1 (en) Pyridazonine herbicides
MD20160095A2 (ro) Derivaţi de pirimidiniloxi-benzen utilizaţi ca erbicide
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
EA201691472A1 (ru) Конденсированные пиримидины в качестве ингибиторов комплекса p97
MX367897B (es) Derivados de piridazinona macrociclicos.
MX375030B (es) Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
MX2017002328A (es) Analogos de dioxolano de uridina para el tratamiento del cancer.
EA201592082A1 (ru) 3,4-дигидроизохинолин-2(1h)-ильные соединения
MX393838B (es) Uso de compuestos heterociclicos para controlar nematodos.
MX2015015786A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
PE20200387A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
MX2017000594A (es) Derivados de bis(aril) catecol como herbicidas.
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
PH12015502462A1 (en) Imidazo-triazine derivatives as pde10 inhibitors
EP2602254A4 (en) HETEROCYCLIC CONNECTION
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
CL2019002203A1 (es) Nuevos compuestos heterocíclicos y sus usos en la prevención o el tratamiento de infecciones bacterianas.